Previous 10 | Next 10 |
2023-12-08 17:07:24 ET More on Ultragenyx Pharmaceutical Ultragenyx: Speculative Innovation Amidst High Expenditures Merits Caution (Rating Downgrade) Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2023 Earnings Call Transcript Ultragenyx Pharmaceutical Inc. 2023 Q3 - Res...
6 th Annual Evercore ISI HealthCONx on November 28 in Miami Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City NOVATO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company fo...
2023-11-14 21:51:36 ET Summary Ultragenyx shows clinical innovation in rare diseases; financial growth is offset by high net loss and cash burn. Recent earnings indicate YOY revenue growth but a substantial net loss; operating expenses have decreased. Ultragenyx's liquid asset...
NOVATO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the c...
2023-11-02 22:29:10 ET Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2023 Earnings Conference Call November 02, 2023 05:00 PM ET Company Participants Joshua Higa - Vice President of Investor Relations Emil Kakkis - Chief Executive Officer & President Erik Harris ...
2023-11-02 17:01:04 ET More on Ultragenyx Pharmaceutical Ultragenyx: Market Expectations Revised Lower, Awaiting Clinical Trial Catalysts (Rating Downgrade) Ultragenyx Pharmaceutical prices $300 million securities offering Seeking Alpha’s Quant Rating on Ultra...
Third quarter 2023 total revenue of $98.1 million, Crysvita ® revenue of $74.9 million and Dojolvi ® revenue of $16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojol...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Ultragenyx Pharmaceutical Inc. (RARE) is expected to report $-2.08 for Q3 2023
2023-11-01 13:17:04 ET More on Ultragenyx Pharmaceutical Ultragenyx: Market Expectations Revised Lower, Awaiting Clinical Trial Catalysts (Rating Downgrade) Ultragenyx Pharmaceutical prices $300 million securities offering Seeking Alpha’s Quant Rating on Ultra...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...